Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 170

Sort by

Sort Order Select

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2025-5994

Published: 2025

Journal Articles

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Blood (2025) 146 (Supplement 1): 5951.

https://doi.org/10.1182/blood-2025-5951

Published: 2025

Journal Articles

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Blood (2025) 146 (Supplement 1): 592.

https://doi.org/10.1182/blood-2025-592

Published: 2025

Journal Articles

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Michelle Nwachukwu, Wei-Ying Jen, Jeremy Ramdial, Caitlin Rausch, Roberta Santos Azevedo, Gautam Borthakur, Courtney DiNardo, Naval Daver, Betul Oran, Richard Champlin, Elizabeth Shpall, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 6975.

https://doi.org/10.1182/blood-2025-6975

Published: 2025

Journal Articles

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Blood (2025) 146 (Supplement 1): 4294.

https://doi.org/10.1182/blood-2025-4294

Published: 2025

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Blood (2025) 146 (Supplement 1): 378.

https://doi.org/10.1182/blood-2025-378

Published: 2025

Journal Articles

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Blood (2025) 146 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2025-1869

Published: 2025

Journal Articles

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Yosra Aljawai, Denai Milton, Rohtesh Mehta, David Marin, Yago Nieto, George Chen, Betul Oran, Portia Smallbone, Chitra Hosing, Oren Pasvolsky, Amin Alousi, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 168.

https://doi.org/10.1182/blood-2025-168

Published: 2025

Journal Articles

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Blood (2025) 146 (Supplement 1): 6058.

https://doi.org/10.1182/blood-2025-6058

Published: 2025

Journal Articles

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation

Betul Oran, Peter Thall, Jeremy Ramdial, Portia Smallbone, Roland Bassett, David Marin, Richard Champlin, Elizabeth Shpall, Partow Kebriaei

Blood (2025) 146 (Supplement 1): 2515.

https://doi.org/10.1182/blood-2025-2515

Published: 2025

Journal Articles

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

Betul Oran, Peter Thall, Gheath Alatrash, Jin Im, Jeremy Ramdial, Roland Bassett, Uday Popat, Partow Kebriaei, Portia Smallbone, Jessica Jewell, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 2511.

https://doi.org/10.1182/blood-2025-2511

Published: 2025

Journal Articles

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 6075.

https://doi.org/10.1182/blood-2025-6075

Published: 2025

Journal Articles

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2024-206801

Published: 2024

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Yosra M. Aljawai, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Portia Smallbone, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2024) 144 (Supplement 1): 7441.

https://doi.org/10.1182/blood-2024-210279

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Rima M. Saliba, Yosra M. Aljawai, Amin M. Alousi, Betul Oran, Uday Popat, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 4890.

https://doi.org/10.1182/blood-2024-210660

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Allogeneic stem cell transplantation-related outcomes in chronic myelomonocytic leukemia: Data from a large academic center

Optimizing essential, complex hematologic care for patients living with disabilities

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

Impact of pre-allogeneic stem cell transplantation (SCT) disease characteristics, therapy, and response on post-SCT outcomes in higher risk myelodysplastic syndromes

Comprehensive Characteristics and Outcomes of Myeloid Neoplasms Following Chimeric Antigen Receptor T-Cell Therapy for Other Hematologic Malignancies

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Predictors of Graft-Versus-Host Disease with Post-Transplant Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only